GCG and type 2 diabetes mellitus: In addition to its glucose-lowering effects, large prospective outcome trials with GLP-1 RAs showed significant reduction of the risk of CV events and mortality in T2DM patients, particularly for liraglutide, semaglutide, albiglutide, and dulaglutide [180,181,182,183].